JP2016537414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537414A5 JP2016537414A5 JP2016552222A JP2016552222A JP2016537414A5 JP 2016537414 A5 JP2016537414 A5 JP 2016537414A5 JP 2016552222 A JP2016552222 A JP 2016552222A JP 2016552222 A JP2016552222 A JP 2016552222A JP 2016537414 A5 JP2016537414 A5 JP 2016537414A5
- Authority
- JP
- Japan
- Prior art keywords
- neural crest
- cells
- cardiac neural
- cardiac
- micrometer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000747 cardiac effect Effects 0.000 claims description 27
- 210000000130 stem cell Anatomy 0.000 claims description 25
- 230000004069 differentiation Effects 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 210000004165 myocardium Anatomy 0.000 claims description 3
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 210000001982 neural crest cell Anatomy 0.000 claims 20
- 108020003175 receptors Proteins 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 9
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 7
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims 5
- 238000012258 culturing Methods 0.000 claims 5
- 102000045246 noggin Human genes 0.000 claims 5
- 108700007229 noggin Proteins 0.000 claims 5
- 208000013875 Heart injury Diseases 0.000 claims 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 claims 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 101100315385 Drosophila melanogaster tsg gene Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- 101100154843 Xenopus laevis twsg1-b gene Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000933 neural crest Anatomy 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 102000003702 retinoic acid receptors Human genes 0.000 claims 1
- 108090000064 retinoic acid receptors Proteins 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 101150060270 twsg1a gene Proteins 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 3
- 102000000327 E2F4 Transcription Factor Human genes 0.000 description 2
- 108010016085 E2F4 Transcription Factor Proteins 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 235000007849 Lepidium sativum Nutrition 0.000 description 1
- 244000211187 Lepidium sativum Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896945P | 2013-10-29 | 2013-10-29 | |
| US61/896,945 | 2013-10-29 | ||
| PCT/US2014/062939 WO2015066197A2 (en) | 2013-10-29 | 2014-10-29 | Cardiac neural crest cells and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000020A Division JP6832049B2 (ja) | 2013-10-29 | 2019-01-04 | 心臓神経堤細胞、及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016537414A JP2016537414A (ja) | 2016-12-01 |
| JP2016537414A5 true JP2016537414A5 (enExample) | 2017-12-14 |
Family
ID=53005371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552222A Pending JP2016537414A (ja) | 2013-10-29 | 2014-10-29 | 心臓神経堤細胞、及びその使用方法 |
| JP2019000020A Expired - Fee Related JP6832049B2 (ja) | 2013-10-29 | 2019-01-04 | 心臓神経堤細胞、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000020A Expired - Fee Related JP6832049B2 (ja) | 2013-10-29 | 2019-01-04 | 心臓神経堤細胞、及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10786536B2 (enExample) |
| EP (1) | EP3063267A4 (enExample) |
| JP (2) | JP2016537414A (enExample) |
| WO (1) | WO2015066197A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962409B2 (en) | 2007-10-01 | 2018-05-08 | Vestion, Inc. | Therapy using cardiac stem cells and mesenchymal stem cells |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN104114171A (zh) | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| ES2824165T3 (es) | 2012-11-30 | 2021-05-11 | Vestion Inc | Células madre cardíacas y métodos de identificación y uso de las mismas |
| EP3426302B1 (en) | 2016-03-10 | 2022-12-14 | IO Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
| DK3426303T3 (da) * | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner |
| KR102503086B1 (ko) * | 2017-09-08 | 2023-02-23 | 가부시키가이샤 오츠카 세이야쿠 고죠 | 어린 돼지 유래 줄기 세포 및 그 제조 방법 |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS |
| BR112020010539A2 (pt) | 2017-11-30 | 2020-11-17 | Kyoto University | métodos para produção e para proliferação de células da crista neural, para produção de células nervosas, células da glia, células estromais mesenquimais, células ósseas, condrócitos, células da córnea ou células pigmentares e para cultivar células da crista neural, meio, estoque congelado, e, uso de um meio |
| CN108300722A (zh) * | 2018-02-11 | 2018-07-20 | 南京市妇幼保健院 | 用于检测先天性心脏病的基因panel及应用 |
| CN110652515A (zh) * | 2018-06-29 | 2020-01-07 | 中国科学院深圳先进技术研究院 | AMPK抑制剂Compound C在治疗肿瘤药物中的应用 |
| WO2022020794A1 (en) * | 2020-07-24 | 2022-01-27 | The Scripps Research Institute | Compositions comprising neural crest cell derivatives and uses thereof |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1007631T4 (da) | 1997-07-14 | 2009-04-27 | Osiris Therapeutics Inc | Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller |
| US6821740B2 (en) | 1998-02-25 | 2004-11-23 | Becton, Dickinson And Company | Flow cytometric methods for the concurrent detection of discrete functional conformations of PRB in single cells |
| AU5545499A (en) | 1998-07-31 | 2000-02-21 | Genzyme Corporation | Improvement of cardiac function by mesenchymal stem cell transplantation |
| US8075881B2 (en) | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US6930222B2 (en) | 2000-08-22 | 2005-08-16 | The Scripps Research Institute | In vivo animal model of human leukemia |
| AU2003270051A1 (en) | 2002-08-29 | 2004-03-19 | Baylor College Of Medicine | Heart derived cells for cardiac repair |
| CA2528869A1 (en) | 2003-06-12 | 2004-12-23 | Regents Of The University Of Minnesota | Directing cells to target tissues or organs |
| US7082573B2 (en) | 2003-07-30 | 2006-07-25 | America Online, Inc. | Method and system for managing digital assets |
| BRPI0414961A (pt) * | 2003-10-03 | 2006-11-07 | Keiichi Fukuda | processo de indução da diferenciação de células tronco em células do miocárdio |
| DE602004024125D1 (de) | 2003-12-25 | 2009-12-24 | Kanazawa University Technology | Induktion einer myokardzelle unter verwendung einer säuger-knochenmarkzelle oder aus nabelschnurblut stammenden zelle und fettgewebe |
| WO2006039630A2 (en) | 2004-10-02 | 2006-04-13 | Indiana University Research & Technology Corporation | Materials and methods for identifying compounds that modulate the cell cycle |
| WO2008054819A2 (en) | 2006-11-02 | 2008-05-08 | The General Hospital Corporation | Cardiovascular stem cells, methods for stem cell isolation, and uses thereof |
| EP2079831A2 (en) * | 2006-11-07 | 2009-07-22 | Keck Graduate Institute | Enriched stem cell and progenitor cell populations, and methods of producing and using such populations |
| US9962409B2 (en) | 2007-10-01 | 2018-05-08 | Vestion, Inc. | Therapy using cardiac stem cells and mesenchymal stem cells |
| WO2009073618A2 (en) * | 2007-11-30 | 2009-06-11 | New York Medical College | Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
| US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
| AU2010355614B2 (en) | 2010-06-13 | 2015-07-02 | Institute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof |
| EP3399026B1 (en) * | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EP2750509B1 (en) * | 2011-08-30 | 2016-12-28 | The J. David Gladstone Institutes | Methods for generating cardiomyocytes |
| US20140162366A1 (en) * | 2012-08-31 | 2014-06-12 | Salk Institute For Biological Studies | Generation of vascular progenitor cells |
| ES2824165T3 (es) | 2012-11-30 | 2021-05-11 | Vestion Inc | Células madre cardíacas y métodos de identificación y uso de las mismas |
| US11377639B2 (en) * | 2013-11-15 | 2022-07-05 | Wisconsin Alumni Research Foundation | Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors |
-
2014
- 2014-10-29 EP EP14858818.9A patent/EP3063267A4/en not_active Ceased
- 2014-10-29 US US15/032,965 patent/US10786536B2/en active Active - Reinstated
- 2014-10-29 JP JP2016552222A patent/JP2016537414A/ja active Pending
- 2014-10-29 WO PCT/US2014/062939 patent/WO2015066197A2/en not_active Ceased
-
2019
- 2019-01-04 JP JP2019000020A patent/JP6832049B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-28 US US17/034,883 patent/US20210260133A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537414A5 (enExample) | ||
| Fu et al. | MicroRNA-338 in MSCs-derived exosomes inhibits cardiomyocyte apoptosis in myocardial infarction. | |
| Keshtkar et al. | Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine | |
| Taran et al. | In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources | |
| Mashiko et al. | How does fat survive and remodel after grafting? | |
| Eom et al. | Mesenchymal stem cell therapy for cirrhosis: present and future perspectives | |
| Dorronsoro et al. | Regenerating the injured kidney with human umbilical cord mesenchymal stem cell-derived exosomes | |
| Cao et al. | Clinical-grade human umbilical cord-derived mesenchymal stem cells reverse cognitive aging via improving synaptic plasticity and endogenous neurogenesis | |
| BR112015017338A2 (pt) | anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios | |
| Warrier et al. | Inherent propensity of amnion-derived mesenchymal stem cells towards endothelial lineage: vascularization from an avascular tissue | |
| Liu et al. | Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis | |
| Kadota et al. | Pluripotent stem cell-derived cardiomyocyte transplantation for heart disease treatment | |
| JP2015205894A5 (enExample) | ||
| Liao et al. | Adipose tissue-derived stem cells promote the reversion of non-alcoholic fatty liver disease: an in vivo study | |
| JP2019506396A5 (enExample) | ||
| Pratheesh et al. | Comparative study on characterization and wound healing potential of goat (Capra hircus) mesenchymal stem cells derived from fetal origin amniotic fluid and adult bone marrow | |
| BR112022018101A2 (pt) | Células hepáticas tipo tronco para tratamento e/ou prevenção de distúrbios hepáticos fulminantes | |
| Klopsch et al. | Cardiac mesenchymal stem cells proliferate early in the ischemic heart | |
| Soltani et al. | Role of signaling pathways during cardiomyocyte differentiation of mesenchymal stem cells | |
| EP3233097A1 (en) | Improved cell therapies | |
| Ma et al. | Isolation and biological characterization of a novel type of pulmonary mesenchymal stem cells derived from Wuzhishan miniature pig embryo | |
| Schoenfeld et al. | The existence of myocardial repair: mechanistic insights and enhancements | |
| Vu et al. | Human menstrual blood-derived stem cell transplantation for acute hind limb ischemia treatment in mouse models | |
| Dehghan et al. | Transplantation of cardiogenic pre-differentiated autologous adipose-derived mesenchymal stem cells induced by mechanical loading improves cardiac function following acute myocardial infarction in rabbit model | |
| CN106573018A (zh) | 用于治疗骨骼缺损的体干细胞 |